Imipramine inhibition of TRPM-like plasmalemmal Mg2+transport in vascular smooth muscle cells
Imipramine inhibition of TRPM-like plasmalemmal Mg2+transport in vascular smooth muscle cells
复制标题
DOI:
10.1111/j.1582-4934.2010.01024.x
复制
发表时间:
2011-03-01
影响因子:
5.3
通讯作者:
Nakayama, Shinsuke
中科院分区:
文献类型:
--
作者:
Hamaguchi, Yukihisa;Tatematsu, Yasushi;Nakayama, Shinsuke
Depression is associated with vascular disease, such as myocardial infarction and stroke. Pharmacological treatments may contribute to this association. On the other hand, Mg2+ deficiency is also known to be a risk factor for the same category of diseases. In the present study, we examined the effect of imipramine on Mg2+ homeostasis in vascular smooth muscle, especially via melastatin-type transient receptor potential (TRPM)-like Mg2+-permeable channels. The intracellular free Mg2+ concentration ([Mg2+](i)) was measured using 31P-nuclear magnetic resonance (NMR) in porcine carotid arteries that express both TRPM6 and TRPM7, the latter being predominant. pH(i) and intracellular phosphorus compounds were simultaneously monitored. To rule out Na+-dependent Mg2+ transport, and to facilitate the activity of Mg2+-permeable channels, experiments were carried out in the absence of Na+ and Ca2+. Changing the extracellular Mg2+ concentration to 0 and 6 mM significantly decreased and increased [Mg2+](i), respectively, in a time-dependent manner. Imipramine statistically significantly attenuated both of the bi-directional [Mg2+](i) changes under the Na+- and Ca2+-free conditions. This inhibitory effect was comparable in influx, and much more potent in efflux to that of 2-aminoethoxydiphenyl borate, a well-known blocker of TRPM7, a channel that plays a major role in cellular Mg2+ homeostasis. Neither [ATP](i) nor pH(i) correlated with changes in [Mg2+](i). The results indicate that imipramine suppresses Mg2+-permeable channels presumably through a direct effect on the channel domain. This inhibitory effect appears to contribute, at least partially, to the link between antidepressants and the risk of vascular diseases.